Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

NCT05512416 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: dalpiciclib plus letrozole

Sponsor

The Affiliated Hospital of Qingdao University

Collaborators

[object Object]